Immunodermatology News

Bimekizumab for the treatment of moderate to severe hidradenitis suppurativa met the primary endpoint and key secondary endpoint in two phase 3 studies, UCB announced in a press release.

Following an ED visit for hidradenitis suppurativa treatment, patients had a low rate of dermatology outpatient follow-up and a high rate of return ED visits for HS treatment within 180 days, according to a study.

Diagnosis of discoid lupus erythematosus in patients aged younger than 25 years may predict the onset of severe systemic lupus erythematosus, according to study findings.

Response-adapted therapy in melanoma, which involves removal of certain immunotherapeutic agents in a combination, can reduce costs without a decrease in efficacy, according to a study.

Proton pump inhibitors may be associated with pharmacovigilance signals for the occurrence of drug-induced lupus erythematosus, according to a research letter published in JAMA Dermatology.

Ruxolitinib cream 1.5% was associated with a significant improvement compared with vehicle in two trials of patients with vitiligo, according to a study.

Earlier this year, a group of researchers published data from long-term extension study of tofacitinib in patients with dermatomyositis, demonstrating a “sustained response” to a pan-JAK inhibitor in this population.

Almirall has announced the initiation of a phase 1 study evaluating ALM27134 for the treatment of autoimmune dermatological diseases, according to a company press release.

MILAN — Deucravacitinib demonstrated efficacy and safety in treating patients with systemic lupus erythematosus and sustained improvement up to 48 weeks.

The RECELL system was successful in repigmenting skin in patients with vitiligo, Avita Medical announced in a press release.